Status:
NOT_YET_RECRUITING
ImmuNe ParameTERs to Predict Immunotherapy REsponse and Toxicity (INTERPRET)
Lead Sponsor:
Indiana University
Collaborating Sponsors:
Indiana Institute of Personalized Medicine
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This is a prospective observational study that will collect blood samples at 1-10 timepoints related to initiation of immunotherapy. The study may collect samples before the start of immunotherapy and...
Detailed Description
The long-term goal of this research is to identify immunologic and other blood-borne markers of immunotherapy efficacy and toxicity. The objective of this proposal is to identify associations between ...
Eligibility Criteria
Inclusion
- ≥ 18 years old at the time of informed consent.
- Have a diagnosis of cancer and initiating therapy with single agent or combination therapy that includes an immunotherapy (see Appendix 16.1 for list of immunotherapy classes).
- Ability to provide written informed consent and HIPAA authorization.
Exclusion
- 1\. Not meeting any of the previously described inclusion criteria.
Key Trial Info
Start Date :
May 1 2026
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2029
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06900296
Start Date
May 1 2026
End Date
April 1 2029
Last Update
October 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, United States, 46202